Otilimab in combination with conventional synthetic DMARDs for treating rheumatoid arthritis


featured image

Otilimab in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) is in clinical development for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response to conventional synthetic DMARDs and/or targeted therapies (biologic DMARDs and Janus Kinase inhibitors).

Interventions: Otilimab
Indications: Rheumatoid arthritis
Therapeutic Areas: Rheumatology
Year: 2022

Otilimab in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) is in clinical development for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response to conventional synthetic DMARDs and/or targeted therapies (biologic DMARDs and Janus Kinase inhibitors). RA is a chronic autoimmune condition where the body’s immune system attacks the joints. It most commonly affects the hands, feet and wrists but can affect any joint on the body, resulting in pain, swelling and difficulty moving. The active disease is often characterised by ‘flares’, where symptoms worsen for a period of time. Medications such as conventional synthetic DMARDs and/or targeted therapies may help control the symptoms and slow the rate of progression. However, some people may have an inadequate response to these treatments and are left with limited options.